Accepted at: Sep, 20, 2024
2:46 a.m.
Author:
phoebeee
Related Deck:
1675118865074
Accepted
Rationale for new note
new card
Text
What antihypertensive classes are contraindicated in patients with bilateral renal artery stenosis?
{{c1::Angiotensin converting enzyme inhibitors (ACEIs)
and
Angiotensin II receptor blockers (ARBs)}}
{{c1::Angiotensin converting enzyme inhibitors (ACEIs)
and
Angiotensin II receptor blockers (ARBs)}}
Text
What <b>antihypertensive classes</b> are <i>contraindicated </i>in patients with <b>bilateral renal artery stenosis</b>?<br><br>{{c1::<b>Angiotensin converting enzyme inhibitors</b> (ACEIs)<br> and <br><b>Angiotensin II receptor blockers</b> (ARBs)}}
Extra
ACE inhibitors and ARBs cause vasodilation of the efferent arteriole in the glomerulus creating a risk of azotemia in patients with severe unilateral or bilateral renal artery stenosis
Extra
<b>ACE inhibitors</b> and <b>ARBs </b>cause vasodilation of the efferent arteriole in the glomerulus creating a risk of <b>azotemia </b>in patients with severe unilateral or <b>bilateral</b> <b>renal artery stenosis</b>
Personal Notes
Empty field
Personal Notes
Missed Questions
Empty field
Missed Questions
Oxford Handbook
Empty field
Oxford Handbook
First Aid
Empty field
First Aid
AMBOSS
Empty field
AMBOSS
eTG Complete
Empty field
eTG Complete
Talley & O'Connor
Empty field
Talley & O'Connor
Additional Resources
Empty field
Additional Resources
Source
eTG - Hypertension and blood pressure reduction https://tgldcdp.tg.org.au/viewTopic?etgAccess=true&guidelinePage=Cardiovascular&topicfile=c_CVG_Hypertension-and-blood-pressure-reductiontopic_1&guidelinename=auto§ionId=c_CVG_Hypertension-and-blood-pressure-reductiontopic_1#c_CVG_Hypertension-and-blood-pressure-reductiontopic_1 Published June 2023, Accessed 19 September 2024
Source
eTG - Hypertension and blood pressure reduction <a href="https://tgldcdp.tg.org.au/viewTopic?etgAccess=true&guidelinePage=Cardiovascular&topicfile=c_CVG_Hypertension-and-blood-pressure-reductiontopic_1&guidelinename=auto§ionId=c_CVG_Hypertension-and-blood-pressure-reductiontopic_1#c_CVG_Hypertension-and-blood-pressure-reductiontopic_1">https://tgldcdp.tg.org.au/viewTopic?etgAccess=true&guidelinePage=Cardiovascular&topicfile=c_CVG_Hypertension-and-blood-pressure-reductiontopic_1&guidelinename=auto&sectionId=c_CVG_Hypertension-and-blood-pressure-reductiontopic_1#c_CVG_Hypertension-and-blood-pressure-reductiontopic_1</a> Published June 2023, Accessed 19 September 2024<br>
One by one
Empty field
One by one
Tags
#Malleus_CM::#Pharmacology::08_Cardiovascular_drugs::03_Antihypertensives::02_ACE_inhibitors::Captopril::04_Contraindications/Precautions
#Malleus_CM::#Pharmacology::08_Cardiovascular_drugs::03_Antihypertensives::02_ACE_inhibitors::Enalapril::04_Contraindications/Precautions
#Malleus_CM::#Pharmacology::08_Cardiovascular_drugs::03_Antihypertensives::02_ACE_inhibitors::Fozinopril::04_Contraindications/Precautions
#Malleus_CM::#Pharmacology::08_Cardiovascular_drugs::03_Antihypertensives::02_ACE_inhibitors::Fosinopril::04_Contraindications/Precautions
#Malleus_CM::#Pharmacology::08_Cardiovascular_drugs::03_Antihypertensives::02_ACE_inhibitors::Lisinopril::04_Contraindications/Precautions
#Malleus_CM::#Pharmacology::08_Cardiovascular_drugs::03_Antihypertensives::02_ACE_inhibitors::Perindopril::04_Contraindications/Precautions
#Malleus_CM::#Pharmacology::08_Cardiovascular_drugs::03_Antihypertensives::02_ACE_inhibitors::Quinapril::04_Contraindications/Precautions
#Malleus_CM::#Pharmacology::08_Cardiovascular_drugs::03_Antihypertensives::02_ACE_inhibitors::Ramipril::04_Contraindications/Precautions
#Malleus_CM::#Pharmacology::08_Cardiovascular_drugs::03_Antihypertensives::02_ACE_inhibitors::Trandolapril::04_Contraindications/Precautions
#Malleus_CM::#Resources_by_Rotation::Internal_Medicine::Cardiology
#Malleus_CM::#Resources_by_Rotation::General_Practice
#Malleus_CM::#Resources_by_Rotation::Internal_Medicine
#Malleus_CM::#eTG_Complete::Cardiovascular::Blood_pressure_reduction::Hypertension_and_blood_pressure_reduction
#Malleus_CM::#Subjects::Cardiology::09_Hypertension::Essential_Hypertension::12_Screening/Prevention
#Malleus_CM::#Pharmacology::08_Cardiovascular_drugs::03_Antihypertensives::03_Sartans::Candesartan::04_Contraindications/Precautions
#Malleus_CM::#Pharmacology::08_Cardiovascular_drugs::03_Antihypertensives::03_Sartans::Eprosartan::04_Contraindications/Precautions
#Malleus_CM::#Pharmacology::08_Cardiovascular_drugs::03_Antihypertensives::03_Sartans::Irbesartan::04_Contraindications/Precautions
#Malleus_CM::#Pharmacology::08_Cardiovascular_drugs::03_Antihypertensives::03_Sartans::Losartan::04_Contraindications/Precautions
#Malleus_CM::#Pharmacology::08_Cardiovascular_drugs::03_Antihypertensives::03_Sartans::Olmesartan::04_Contraindications/Precautions
#Malleus_CM::#Pharmacology::08_Cardiovascular_drugs::03_Antihypertensives::03_Sartans::Telmisartan::04_Contraindications/Precautions
#Malleus_CM::#Pharmacology::08_Cardiovascular_drugs::03_Antihypertensives::03_Sartans::Valsartan::04_Contraindications/Precautions
#Malleus_CM::#Subjects::Cardiology::09_Hypertension::Renal_Artery_Stenosis::11_Complications/Prognosis